Guest: Dr. Raymond Huml, Executive Director of Strategic Drug Development and Head of Global Biosimilars Strategic Planning, Quintiles, Inc.
Topics: Quintiles, regulatory affairs, pharmaceutical due diligence, evolving business models in pharma and CROs, biosimilars
Mar
12
2014